Market Cap : 46.27 M | Enterprise Value : 17.56 M | PE Ratio : At Loss | PB Ratio : 0.60 |
---|
OCX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score -0.69 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for OncoCyte's Beneish M-Score or its related term are showing as below:
During the past 9 years, the highest Beneish M-Score of OncoCyte was 155.37. The lowest was -9.20. And the median was 0.72.
The historical data trend for OncoCyte's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OncoCyte's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, OncoCyte's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where OncoCyte's Beneish M-Score falls in comparison to its industry or sector. The grey bar indicates the Beneish M-Score's extreme value range as defined by GuruFocus.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of OncoCyte for today is based on a combination of the following eight different indices:
M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
= | -4.84 | + | 0.92 * 1.1053 | + | 0.528 * 3.7302 | + | 0.404 * 1.0321 | + | 0.892 * 1.7447 | + | 0.115 * 0.6165 | |
- | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
- | 0.172 * 0.7293 | + | 4.679 * -0.0921 | - | 0.327 * 0.9815 | |||||||
= | -0.69 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep22) TTM: | Last Year (Sep21) TTM: |
Total Receivables was $1.99 Mil. Revenue was 1.017 + 2.067 + 1.424 + 3.589 = $8.10 Mil. Gross Profit was -1.174 + -0.314 + -0.533 + 1.369 = $-0.65 Mil. Total Current Assets was $36.64 Mil. Total Assets was $157.34 Mil. Property, Plant and Equipment(Net PPE) was $11.59 Mil. Depreciation, Depletion and Amortization(DDA) was $5.19 Mil. Selling, General, & Admin. Expense(SGA) was $36.91 Mil. Total Current Liabilities was $12.95 Mil. Long-Term Debt & Capital Lease Obligation was $2.94 Mil. Net Income was -9.333 + -8.3 + -10.291 + -35.885 = $-63.81 Mil. Non Operating Income was 5.486 + 6.517 + 4.29 + -22.62 = $-6.33 Mil. Cash Flow from Operations was -11.352 + -11.291 + -13.277 + -7.065 = $-42.99 Mil. |
Total Receivables was $1.03 Mil. Revenue was 0.984 + 2.03 + 1.124 + 0.503 = $4.64 Mil. Gross Profit was -0.866 + -0.394 + 0.079 + -0.213 = $-1.39 Mil. Total Current Assets was $47.59 Mil. Total Assets was $168.34 Mil. Property, Plant and Equipment(Net PPE) was $7.64 Mil. Depreciation, Depletion and Amortization(DDA) was $1.80 Mil. Selling, General, & Admin. Expense(SGA) was $29.01 Mil. Total Current Liabilities was $13.38 Mil. Long-Term Debt & Capital Lease Obligation was $3.94 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
= | (1.99 / 8.097) | / | (1.032 / 4.641) | |
= | 0.24577004 | / | 0.22236587 | |
= | 1.1053 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
= | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
= | (-1.394 / 4.641) | / | (-0.652 / 8.097) | |
= | -0.3003663 | / | -0.08052365 | |
= | 3.7302 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
= | (1 - (36.636 + 11.593) / 157.344) | / | (1 - (47.591 + 7.637) / 168.341) | |
= | 0.69348053 | / | 0.67192781 | |
= | 1.0321 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
SGI | = | Sales_t | / | Sales_t-1 |
= | Revenue_t | / | Revenue_t-1 | |
= | 8.097 | / | 4.641 | |
= | 1.7447 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
= | (1.8 / (1.8 + 7.637)) | / | (5.194 / (5.194 + 11.593)) | |
= | 0.19073858 | / | 0.30940609 | |
= | 0.6165 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
= | (36.912 / 8.097) | / | (29.012 / 4.641) | |
= | 4.55872545 | / | 6.25123896 | |
= | 0.7293 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
= | ((2.935 + 12.952) / 157.344) | / | ((3.94 + 13.377) / 168.341) | |
= | 0.10096985 | / | 0.10286858 | |
= | 0.9815 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
= | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
= | (-63.809 - -6.327 | - | -42.985) | / | 157.344 | |
= | -0.0921 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
OncoCyte has a M-score of -0.69 signals that the company is likely to be a manipulator.
Thank you for viewing the detailed overview of OncoCyte's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Josh Riggs | officer: Interim CEO | 15 CUSHING, IRVINE CA 92618 |
Lou Silverman | director | |
James Yang Liu | officer: Controller, PAO | C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618 |
John Peter Gutfreund | director | C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618 |
Anish M. John | officer: SVP, Finance, and Interim CFO | C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618 |
Pura Vida Investments, Llc | 10 percent owner | 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011 |
Efrem Kamen | 10 percent owner | C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011 |
Gisela Paulsen | officer: Chief Operating Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Li Yu | officer: VP Cntrllr/Prncpl Acctng Offcr | 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660 |
Jennifer L. Carter | director | C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Douglas T. Ross | officer: Chief Medical Officer | 15 CUSHING, IRVINE CA 92618 |
Tony T Kalajian | officer: SVP-Chief Accounting Officer | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Melinda Griffith | director | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Padma Sundar | officer: SVP, Marketing & Market Access | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Ronald Asbury Andrews | director | 5791 VAN ALLEN WAY, CARLSBAD CA 92008 |
From GuruFocus
By GuruFocusNews 05-26-2022
By Value_Insider 12-01-2022
By GuruFocusNews 06-15-2022
By PurpleRose 08-01-2022
Other Sources
By Zacks 2022-05-05
By Seekingalpha 2022-08-11
By Zacks 2022-09-23
By Seekingalpha 2022-03-10
By tipranks.com 2022-08-11
By Seekingalpha 2022-11-19
By Zacks 2022-11-10
By Zacks 2022-07-27
By Zacks 2022-11-16
By tipranks.com 2022-03-11
By Zacks 2022-02-23
By Zacks 2022-05-11
By Zacks 2022-09-02
By Zacks 2022-03-10
By tipranks.com 2022-07-13